These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 21586917

  • 21. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients.
    Javitt DC.
    Curr Opin Psychiatry; 2006 Mar; 19(2):151-7. PubMed ID: 16612195
    [Abstract] [Full Text] [Related]

  • 22. New perspectives on biological treatment of schizophrenia.
    Lingjaerde O.
    Acta Psychiatr Scand Suppl; 1994 Mar; 384():102-7. PubMed ID: 7879631
    [Abstract] [Full Text] [Related]

  • 23. Alterations of dopamine and serotonin transmission in schizophrenia.
    Remington G.
    Prog Brain Res; 2008 Mar; 172():117-40. PubMed ID: 18772030
    [Abstract] [Full Text] [Related]

  • 24. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia.
    Heresco-Levy U.
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):827-44. PubMed ID: 16262565
    [Abstract] [Full Text] [Related]

  • 25. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
    Heusler P, Newman-Tancredi A, Loock T, Cussac D.
    Eur J Pharmacol; 2008 Feb 26; 581(1-2):37-46. PubMed ID: 18190908
    [Abstract] [Full Text] [Related]

  • 26. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC.
    Int Rev Neurobiol; 2007 Feb 26; 78():69-108. PubMed ID: 17349858
    [Abstract] [Full Text] [Related]

  • 27. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia.
    Haleem DJ.
    J Coll Physicians Surg Pak; 2006 Aug 26; 16(8):556-62. PubMed ID: 16899192
    [Abstract] [Full Text] [Related]

  • 28. Current and novel approaches to the drug treatment of schizophrenia.
    Rowley M, Bristow LJ, Hutson PH.
    J Med Chem; 2001 Feb 15; 44(4):477-501. PubMed ID: 11170639
    [No Abstract] [Full Text] [Related]

  • 29. Biological perspectives: the role of glutamate in schizophrenia and its treatment.
    Steele D, Moore RL, Swan NA, Grant JS, Keltner NL.
    Perspect Psychiatr Care; 2012 Jul 15; 48(3):125-8. PubMed ID: 22724397
    [Abstract] [Full Text] [Related]

  • 30. Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations?
    Dunlop J, Brandon NJ.
    J Psychopharmacol; 2015 Feb 15; 29(2):230-8. PubMed ID: 25586401
    [Abstract] [Full Text] [Related]

  • 31. Psychopharmacological treatment of schizophrenia: what do we have, and what could we get?
    Ellenbroek BA.
    Neuropharmacology; 2012 Mar 15; 62(3):1371-80. PubMed ID: 21420988
    [Abstract] [Full Text] [Related]

  • 32. Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials.
    Rao NP, Remington G.
    Expert Opin Investig Drugs; 2013 Jul 15; 22(7):881-94. PubMed ID: 23639138
    [Abstract] [Full Text] [Related]

  • 33. Progress in the development of neurokinin 3 modulators for the treatment of schizophrenia: molecule development and clinical progress.
    Dawson LA, Porter RA.
    Future Med Chem; 2013 Sep 15; 5(13):1525-46. PubMed ID: 24024945
    [Abstract] [Full Text] [Related]

  • 34. Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials.
    Miyamoto S, Jarskog LF, Fleischhacker WW.
    Curr Opin Psychiatry; 2013 Mar 15; 26(2):158-65. PubMed ID: 23286991
    [Abstract] [Full Text] [Related]

  • 35. Discovery and Development of Non-Dopaminergic Agents for the Treatment of Schizophrenia: Overview of the Preclinical and Early Clinical Studies.
    Jankowska A, Satała G, Partyka A, Wesołowska A, Bojarski AJ, Pawłowski M, Chłoń-Rzepa G.
    Curr Med Chem; 2019 Mar 15; 26(25):4885-4913. PubMed ID: 31291870
    [Abstract] [Full Text] [Related]

  • 36. New Therapeutic Targets and Drugs for Schizophrenia Beyond Dopamine D2 Receptor Antagonists.
    Peng A, Chai J, Wu H, Bai B, Yang H, He W, Zhao Y.
    Neuropsychiatr Dis Treat; 2024 Mar 15; 20():607-620. PubMed ID: 38525480
    [Abstract] [Full Text] [Related]

  • 37. Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia.
    Kim DH, Maneen MJ, Stahl SM.
    Neurotherapeutics; 2009 Jan 15; 6(1):78-85. PubMed ID: 19110200
    [Abstract] [Full Text] [Related]

  • 38. Glutamate and schizophrenia: beyond the dopamine hypothesis.
    Coyle JT.
    Cell Mol Neurobiol; 2006 Jan 15; 26(4-6):365-84. PubMed ID: 16773445
    [Abstract] [Full Text] [Related]

  • 39. [Current state and vision of the development of new antipsychotic drugs].
    Takekita Y, Kinoshita T.
    Nihon Rinsho; 2013 Apr 15; 71(4):730-6. PubMed ID: 23678608
    [Abstract] [Full Text] [Related]

  • 40. Novel antipsychotics in schizophrenia.
    Mortimer AM.
    Expert Opin Investig Drugs; 2004 Apr 15; 13(4):315-29. PubMed ID: 15102583
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.